Menu
Fechar
hrs4r
 I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.
Publications
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E

BCL3-rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.

Haematologica, 2024, 109, 493-508 dx.doi.org/10.3324/haematol.2023.283209
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Haematologica, 2024, 109, 543-552 dx.doi.org/10.3324/haematol.2023.283342
Muñoz NG, Ortega S, Solanich X, Cid J, Díaz M, Moreno AB, Ancochea Á, Santos M, Hernández I, Sanchez JM, Luaña A, García J, Escoda L, Medina L, Ferrer GJ, López J, Céspedes R, Díaz JA, Pons V, Valcárcel D, Grifols JR

Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group.

BLOOD TRANSFUSION, 2024, 22, 176-184 dx.doi.org/10.2450/BloodTransfus.522
Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L, Grupo Español de Leucemia Mieloide Crónica (GELMC)

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.

Journal of Clinical Medicine, 2024, 13 dx.doi.org/10.3390/jcm13030779
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J

Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.

SCIENTIFIC REPORTS, 2024, 14, 7400-7400 dx.doi.org/10.1038/s41598-024-57570-5
Mosquera-Orgueira A, Arellano-Rodrigo E, Garrote M, Martín I, Pérez-Encinas M, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, Heras NL, Magro E, Pérez-Míguez C, Crucitti D, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Nangalia J, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC, Spanish MPN Group (GEMFIN)

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

HemaSphere, 2024, 8 dx.doi.org/10.1002/hem3.60
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R, Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español d

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

ANNALS OF HEMATOLOGY, 2023, 102, 429-437 dx.doi.org/10.1007/s00277-022-05011-6
González-Gil C, Morgades M, Lopes T, Fuster-Tormo F, García-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosín L, Mercadal S, González-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortés C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza PL, Queipo MP, Martínez-Sánchez P, Giménez A, González-Martínez T, Cladera A, Cervera J, Fernández-Martín R, Ardaiz MÁ, Vidal MJ, Baena Á, López-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera JM, Genescà E

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Haematologica, 2023, 108, 969-980 dx.doi.org/10.3324/haematol.2022.281196
Oliveira AC, Roncero JM, Ferrá C, Do Nascimento J, Rodriguez-Luaces M, Encuentra M, Domingo-Domenech E, López P, Gallardo D, Ribera JM, Sarrá J, Sureda A, González-Barca E

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117, 388-397 dx.doi.org/10.1007/s12185-022-03488-5
Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, de Llano MPQ, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

HemaSphere, 2023, 7 dx.doi.org/10.1097/HS9.0000000000000810
Competitive projects
Haematology

Genotipo de las moléculas inhibidoras de respuesta inmune: más allá del trasplante alogénico. Banco nacional de ADN de pacientes tratados con terapia CAR-T.

Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III
Haematology

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 6822ZB3KJ Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.
Haematology

Relevancia del genotipo de LAG3 y moléculas checkpoint en el trasplante alogénico de progenitores hematopyéticos.

Codi oficial: Projecte IJC - Dr. David Gallardo Start date:01/07/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu